Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Study designs for dose-ranging.

L B Sheiner1, S L Beal, N C Sambol

  • 1Department of Laboratory Medicine, School of Medicine, University of California, San Francisco 94143.

Clinical Pharmacology and Therapeutics
|July 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria.

Clinical pharmacology and therapeutics·2015
Same author

Pharmacodynamic measurements of methyl nicotinate percutaneous absorption.

Pharmaceutical research·2013
Same author

CYP2A6 genotype but not age determines cotinine half-life in infants and children.

Clinical pharmacology and therapeutics·2013
Same author

A new Bayesian method to forecast and fine tune individual hemodialysis dose.

Hemodialysis international. International Symposium on Home Hemodialysis·2009
Same author

Ways to fit a PK model with some data below the quantification limit.

Journal of pharmacokinetics and pharmacodynamics·2002
Same author

Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance.

Journal of pharmacokinetics and pharmacodynamics·2001

This study proposes a new approach to premarketing drug dose-ranging studies, moving beyond current FDA procedures. It suggests using parametric models for patient-specific dose-response curves to optimize initial and incremental dosing strategies.

Area of Science:

  • Pharmacology
  • Biostatistics
  • Clinical Trial Design

Background:

  • Current premarketing dose-ranging studies establish initial drug doses using a model assuming dose-response independence.
  • The U.S. Food and Drug Administration (FDA) procedure involves parallel-dose designs with placebo run-in periods.
  • Existing methods offer limited insight into dose-response curve distribution and interpatient variability.

Purpose of the Study:

  • To propose a revised conceptual framework and methodology for drug dose-ranging studies.
  • To introduce parametric models for patient-specific dose-response curves.
  • To enhance the selection of initial and incremental doses for improved clinical trial efficiency and ethics.

Main Methods:

  • Utilizing parametric models to describe patient-specific dose-response relationships.

Related Experiment Videos

  • Leveraging population distribution of these curves to inform initial dose selection.
  • Employing Bayes' rule for adaptive incremental dose adjustments based on individual patient response.
  • Comparing parallel-dose, crossover, and dose-escalation designs.

    • Main Results:

    • Parametric models provide a basis for selecting initial doses that achieve specific responses in a defined patient fraction.
    • Bayesian methods allow for personalized dose adjustments.
    • Dose-escalation designs, when using parametric models, offer comparable information to crossover designs.
    • Dose-escalation designs present ethical advantages, enabling broader patient and clinical setting representation.

    Conclusions:

    • A shift towards parametric patient-specific dose-response modeling is recommended for dose-ranging studies.
    • This approach improves the estimation of dose-response curves and interpatient variability.
    • Dose-escalation designs with parametric models are efficient, ethical, and facilitate more representative study populations.